

Cara Therapeutics, Inc.  
Form 8-K  
March 28, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 28, 2017**

**CARA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**4 Stamford Plaza**

**001-36279**  
**(Commission**

**File Number)**

**06902**

**75-3175693**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Cara Therapeutics, Inc. - Form 8-K

**107 Elm Street 9<sup>th</sup> Floor**

**Stamford, Connecticut**

**(Address of principal executive  
offices)**

**(Zip Code)**

**Registrant's telephone number, including area code (203) 406-3700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2.):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On March 28, 2017, Cara Therapeutics, Inc. issued a press release announcing results from Part A of its two-part Phase 2/3 adaptive design trial of its product candidate, I.V. CR845, in dialysis patients suffering from moderate-to-severe uremic pruritus. A copy of this press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated March 28, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARA THERAPEUTICS, INC.**

By: /s/ Josef Schoell  
Josef Schoell  
Chief Financial Officer  
(Principal Financial and Accounting  
Officer)

Date: March 28, 2017